ストックスクリーナーアプリを入手
37.07
2.83%
1.02
前日終値:
$36.05
開ける：
$36.55
24時間の取引高:
2.33M
Relative Volume:
0.95
時価総額：
$22.79B
収益：
$3.91B
当期純損益:
$823.88M
株価収益率:
27.95
EPS:
1.3262
ネットキャッシュフロー:
$875.28M
1週間 パフォーマンス:
+6.68%
1か月 パフォーマンス:
+12.20%
6か月 パフォーマンス:
+31.08%
1年 パフォーマンス:
+16.39%
1日の値動き範囲:
$36.33
$37.15
1週間の範囲:
$35.02
$40.17
52週間の値動き範囲:
$23.62
$40.17
Genmab Adr Stock (GMAB) Company Profile
Compare GMAB vs VRTX, MRNA, REGN, ARGX, RVMD
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
GMAB
Genmab Adr
|
37.07 | 21.72B | 3.91B | 823.88M | 875.28M | 1.3262 |
VRTX
Vertex Pharmaceuticals Inc
|
510.08 | 127.93B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
225.00 | 79.40B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
746.54 | 81.13B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
825.03 | 60.03B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
189.76 | 43.93B | 742.00K | -1.37B | -1.07B | -7.0731 |
Genmab Adr Stock (GMAB) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-04-22 | アップグレード | Goldman | Neutral → Buy |
| 2026-03-27 | 開始されました | Wolfe Research | Outperform |
| 2026-03-02 | 開始されました | Wells Fargo | Overweight |
| 2026-02-17 | 再開されました | Jefferies | Buy |
| 2026-02-17 | 再開されました | Morgan Stanley | Equal-Weight |
| 2025-09-23 | アップグレード | Guggenheim | Neutral → Buy |
| 2025-04-01 | ダウングレード | Bernstein | Mkt Perform → Underperform |
| 2025-03-11 | アップグレード | William Blair | Mkt Perform → Outperform |
| 2025-02-13 | アップグレード | Leerink Partners | Market Perform → Outperform |
| 2024-10-08 | 開始されました | Redburn Atlantic | Buy |
| 2024-09-04 | 再開されました | Morgan Stanley | Equal-Weight |
| 2024-08-20 | ダウングレード | JP Morgan | Overweight → Neutral |
| 2024-07-15 | アップグレード | RBC Capital Mkts | Sector Perform → Outperform |
| 2024-02-23 | アップグレード | BMO Capital Markets | Market Perform → Outperform |
| 2024-01-22 | ダウングレード | Citigroup | Neutral → Sell |
| 2023-12-06 | アップグレード | UBS | Neutral → Buy |
| 2023-11-10 | アップグレード | Deutsche Bank | Hold → Buy |
| 2023-11-08 | アップグレード | DNB Markets | Sell → Buy |
| 2023-10-18 | 開始されました | Exane BNP Paribas | Underperform |
| 2023-09-06 | ダウングレード | RBC Capital Mkts | Outperform → Sector Perform |
| 2023-08-24 | 開始されました | BTIG Research | Buy |
| 2023-07-14 | 開始されました | HSBC Securities | Buy |
| 2023-05-31 | 開始されました | UBS | Neutral |
| 2023-05-12 | 開始されました | Morgan Stanley | Underweight |
| 2022-12-20 | ダウングレード | Citigroup | Buy → Neutral |
| 2022-11-14 | 開始されました | William Blair | Mkt Perform |
| 2022-11-11 | ダウングレード | Deutsche Bank | Buy → Hold |
| 2022-06-24 | 開始されました | BMO Capital Markets | Market Perform |
| 2022-05-02 | 開始されました | Cowen | Market Perform |
| 2022-03-16 | アップグレード | UBS | Neutral → Buy |
| 2022-01-31 | アップグレード | H.C. Wainwright | Neutral → Buy |
| 2022-01-03 | ダウングレード | Guggenheim | Buy → Neutral |
| 2021-12-01 | 開始されました | Berenberg | Sell |
| 2021-09-16 | ダウングレード | Jefferies | Buy → Hold |
| 2021-09-07 | ダウングレード | Morgan Stanley | Equal-Weight → Underweight |
| 2021-08-24 | ダウングレード | H.C. Wainwright | Buy → Neutral |
| 2021-04-20 | 開始されました | Deutsche Bank | Buy |
| 2021-01-19 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
| 2020-09-23 | ダウングレード | Bryan Garnier | Neutral → Sell |
| 2020-09-08 | 開始されました | SVB Leerink | Mkt Perform |
| 2020-06-25 | ダウングレード | Credit Suisse | Outperform → Neutral |
| 2020-04-23 | 開始されました | Credit Suisse | Outperform |
| 2020-02-24 | 繰り返されました | H.C. Wainwright | Buy |
| 2020-01-13 | 開始されました | SunTrust | Buy |
| 2019-12-12 | ダウングレード | Deutsche Bank | Buy → Hold |
| 2019-09-13 | アップグレード | BofA/Merrill | Neutral → Buy |
| 2019-09-12 | アップグレード | JP Morgan | Neutral → Overweight |
| 2019-08-12 | 開始されました | Guggenheim | Buy |
| 2019-08-12 | 開始されました | Morgan Stanley | Overweight |
| 2019-08-12 | 開始されました | RBC Capital Mkts | Outperform |
すべてを表示
Genmab Adr (GMAB) 最新ニュース
Weekly Recap: Q4 2026 Phase III readouts and RSU/warrant grants - TradingView
Grant of Restricted Stock Units and Warrants to Employees in Genmab - GlobeNewswire Inc.
Genmab stock heads into the open after a 0.84 percent gain - AD HOC NEWS
symbol__ Stock Quote Price and Forecast - CNN
Genmab stock gains as Kempen raises target to DKK 3,300 - AD HOC NEWS
Genmab stock holds steady after first-half 2026 earnings update - AD HOC NEWS
Genmab stock gains as petosemtamab and Q2 figures draw focus - AD HOC NEWS
Genmab stock gains as petosemtamab Phase 3 start and strong Q2 figures support valuation - AD HOC NEWS
Genmab stock gains as HC Wainwright lifts Q3 earnings estimates and Phase 3 petosemtamab trial begin - AD HOC NEWS
Weekly Recap: Epcoritamab Phase III readout and DKK 44.3m share issuance - TradingView
ETFs Investing in Genmab A/S Sponsored ADR Stocks - TradingView
Genmab stock holds steady as analysts stick to a moderate buy view - AD HOC NEWS
Genmab A/S ADSADR Financials – Balance Sheet, Profit & Loss, Cash Flow - valueresearchonline.com
Genmab stock holds in the mid-$30s as higher 2026 guidance leans on royalty income - ad-hoc-news.de
Genmab stock steadies as 2026 royalty-driven guidance lifts revenue outlook - AD HOC NEWS
Genmab stock holds steady as 2026 royalty-driven guidance is raised - ad-hoc-news.de
Analysts Offer Insights on Healthcare Companies: Genmab (GMAB), Definitive Healthcare Corp (DH) and Atai Beckley N.V. (ATAI) - The Globe and Mail
Genmab A/S Sponsored ADR (NASDAQ:GMAB) Receives Average Recommendation of "Moderate Buy" from Brokerages - MarketBeat
Legacy Wealth Asset Management LLC Grows Stake in Genmab A/S Sponsored ADR $GMAB - MarketBeat
Genmab A/S Q2 Earnings Call Highlights - Yahoo Finance
Quantinno Capital Management LP Grows Position in Genmab A/S Sponsored ADR $GMAB - MarketBeat
Genmab (GMAB) Posts Perfect Technical and Setup Scores in Breakout Setup - ChartMill
SummitTX Capital L.P. Makes New Investment in Genmab A/S Sponsored ADR $GMAB - MarketBeat
Genmab A/S Sponsored ADR $GMAB Shares Bought by Renaissance Technologies LLC - MarketBeat
Genmab/AbbVie lymphoma trial meets main goal, analyst eyes bigger market opportunity - MSN
Barometer Capital Management Inc. Boosts Holdings in Genmab A/S Sponsored ADR $GMAB - MarketBeat
What Makes Genmab A/S Sponsored ADR (GMAB) a Strong Momentum Stock: Buy Now? - MSN
Genmab A/S Sponsored ADR (NASDAQ:GMAB) Given Consensus Recommendation of "Moderate Buy" by Analysts - MarketBeat
Diversify Wealth Management LLC Takes $1.22 Million Position in Genmab A/S Sponsored ADR $GMAB - marketbeat.com
EU Approves Expanded Use of ABBV's Tepkinly in Follicular Lymphoma - TradingView
GMABGenmab ADR Earnings - Finviz
H.C. Wainwright raises Genmab stock price target on trial success - Investing.com
Genmab (GMAB) Shows Modest Gains Amid Consolidation: Support and Resistance Levels in FocusFair Value Gap - dars.gov.et
Genmab/AbbVie Lymphoma Trial Meets Main Goal, Analyst Eyes Bigger Market Opportunity - Sahm
Genmab opens the weekend with a clear strategy focus, shares hold their biotech range - Ad-hoc-news.de
Genmab A/S Sponsored ADR Actuals & Estimates (NASDAQ:GMAB) - TradingView
GE91 Forecast — Price Target — Prediction for 2027 - TradingView
GMAB1/N Forecast — Price Target — Prediction for 2027 - TradingView
GMAB News | GENMAB A/S -SP ADR (NASDAQ:GMAB) - ChartMill
Genmab A/S stock (DK0010272202): Copenhagen shares weaken as investors weigh outlook after updated A - AD HOC NEWS
GMAB Q1 2026 Earnings: EPS Misses Estimates by Over 40% as Stock DeclinesQuarterly Earnings Report - The Legal Advocate
Analysts Offer Insights on Healthcare Companies: Roivant Sciences (ROIV), Crescent Biopharma (CBIO) and Genmab (GMAB) - The Globe and Mail
GMAB Stock Price, Quote & Chart | GENMAB A/S -SP ADR (NASDAQ:GMAB) - ChartMill
GMAB vs. ACAD: Which Stock Is the Better Value Option? - MSN
Genmab A/S stock (DK0010272202): earnings momentum and oncology pipeline keep investors watching - AD HOC NEWS
Genmab stock (DK0010272202): Analyst sentiment shifts as earnings forecasts decline - AD HOC NEWS
Genmab Earnings: Strong Patient Uptake and Diverse Late-Stage Pipeline Support Positive Outlook - Morningstar
Genmab Adr (GMAB) 財務データ
収益
当期純利益
現金流量
EPS
5.32%
大文字化:
|
ボリューム (24 時間):